Share this article on:

Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study

Schommers, Philippa,*; Wyen, Christopha,*; Hentrich, Marcusb; Gillor, Daniela; Zoufaly, Alexanderc; Jensen, Bjoernd; Bogner, Johannes R.e; Thoden, Janf; Wasmuth, Jan C.g; Fätkenheuer, Gerda; Hoffmann, Christianh

doi: 10.1097/QAD.0b013e32835e069d
Research Letters

Out of 302 AIDS-related lymphoma (ARL) patients enrolled in the German ARL cohort study, 18 patients had plasmablastic lymphoma (PBL). Twelve out of 18 patients (67%) have died with a median survival of 4 months (range 0–11 months). In univariate analysis, an intermediate or high international prognostic index score was associated with a significantly lower overall survival and progression-free survival. The predominant cause of death was progressive lymphoma (67%). Our data indicate that the outcome of AIDS-related PBL is still very poor.

aFirst Department of Internal Medicine, University of Cologne, Cologne

bDepartment of Hematology and Oncology, Hospital Harlaching, Munich

cDepartment of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg

dDepartment of Gastroenterology, Hepatology and Infectiology, Düsseldorf University Hospital, Düsseldorf

eDepartment of Internal Medicine IV, Department of Infectious Diseases, University of Munich, Munich

fDepartment of Internal Medicine, University Hospital of Freiburg, Freiburg

gDepartment of Internal Medicine I, University of Bonn, Bonn

hICH Study Center, Hamburg/University of Schleswig Holstein, Campus Kiel, Kiel, Germany.

*Philipp Schommers and Christoph Wyen contributed equally to the writing of the article.

Correspondence to Dr Christoph Wyen, First Department of Internal Medicine, University Hospital of Cologne, Joseph Stelzmann Str. 9, 50924 Cologne, Germany. Tel: +49 221 478 3324; fax: +49 221 478 5915; e-mail: christoph.wyen@uk-koeln.de

Received 23 May, 2012

Revised 9 December, 2012

Accepted 17 December, 2012

© 2013 Lippincott Williams & Wilkins, Inc.